Skip to main content
Premium Trial:

Request an Annual Quote

PAG Conference Opens With Focus on Human Health, Drug Discovery

SAN DIEGO, Jan. 18 (GenomeWeb News) - At what is widely acknowledged as the largest gathering of genomics scientists working on model organisms, the 13th annual Plant and Animal Genome meeting officially opened here yesterday with an unusual focus: human health and drug discovery.


Stephen Heller of NIST welcomed attendees to the conference yesterday, though various workshops and seminars were in session as early as Saturday at the Town & Country hotel and convention center.


With 2,200 attendees -- some 1,950 scientists and a few hundred exhibitors -- at  PAG has grown again, and the community continues to represent a variety of organisms under study and technologies and approaches to study them. "There's quite a lot of very first-rate research in the field," Heller said.


William Haseltine was on hand to deliver the opening talk, entitled "From Bench to Bedside in the 21st Century." At a meeting where most sessions are divided by topics such as soybeans or chickens, the focus of his lecture was a departure from standard PAG fare. For the better part of an hour, Haseltine recounted the history, from his perspective, of the Human Genome Project, beginning with the first time he heard about the concept in 1985.


Haseltine reminded attendees that in the early days many model organism researchers feared that such a project would leach funding from their own research and directed towards human studies. But he noted that many grants were awarded in model organism research in an effort to pave the way for technology development and other advances needed to tackle the human genome. Those grants, he said, were the root of many of today's funding mechanisms for plant and animal research.


Haseltine also spoke about his own background as a molecular biologist, founding Human Genome Sciences, and how genomics has changed the drug-discovery infrastructure within big pharma. In a call to the audience, he made the case that the genomics field needs more comparative genetics information such as identifying conserved genome sequences across multiple species.


A second talk on early stage drug discovery, to have been given by NHGRI's Chris Austin on the institute's new chemical genomics initiative, was canceled at the last minute due to an illness.


The last of the opening talks was more familiar territory to attendees: Elaine Ostrander of NIH presented on genomic studies on complex traits in dog, which has been sequenced by Celera Genomics (1.5x coverage of the poodle) and the Broad Institute (7.6x coverage of the boxer), according to Ostrander. Perhaps the most notable point of her talk, particularly for the model organism community, was her finding that using the 1.5x sequence combined with a dense RH map gave as much information for a comparative genomics study as the nearly 8x sequence -- at a cost of just 20 percent of the higher-quality sequence.


Ostrander also pointed out the potential cost savings of performing genotyping studies for diseases that affect both human and dog: a human whole-genome study would require 500,000 SNPs, while the same study in dogs would take just 10,000 to 15,000 SNPs. A second assembly of the 2.4-gigabase dog genome is expected out next month.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.